DenialHelpUnderstand your adult car-t cell therapy denial. Build a reviewable appeal.
Upload the denial notice, verify the extracted facts, identify missing evidence, and prepare a package for treating-clinician review. The notice and applicable rules determine the available route and deadline.
Start my appeal→
See how it worksThe denial notice
Confirm the payer's stated reason, plan language, dates, and review rights from the actual notice.
Facts and evidence
Keep extracted information linked to its source. Unknown facts stay unknown until you or the clinician confirms them.
Route and review
Classify the next step, verify any deadline, and identify what requires treating-clinician review or signature.
Four clear stages.
Upload your denial — and any clinical records you have
Take a photo, scan, or upload PDFs of the denial letter. Adding labs, prior PA letters, or visit notes makes the appeal stronger — but the denial alone is enough to start.
Confirm a few facts
We pre-fill what was extracted. You confirm, correct, or leave it unknown.
We draft your appeal
A source-linked draft and evidence checklist for treating-clinician review.
Your doctor signs and files
We email the letter to you. Your doctor reviews, signs, and submits.
Common questions
Can I appeal a denied insurance claim for Adult CAR-T cell therapy?
The denial notice and governing plan or program determine whether and how the decision can be challenged. DenialHelp first classifies the route, then organizes the relevant facts and sources. Filing dates vary and must be verified against the actual notice.
What does DenialHelp cost for a Adult CAR-T cell therapy appeal?
$39 for a first-level appeal. Other review levels use the current prices shown on the pricing page. The refund promise concerns the described deliverable, not the insurer's decision.
Who reviews and signs the Adult CAR-T cell therapy appeal letter?
The patient's treating physician reviews and signs the appeal letter before it is submitted to the insurer. DenialHelp drafts the letter; the patient and prescribing physician are responsible for submission. We do not file appeals on behalf of patients.
What treatments are covered under Adult CAR-T cell therapy?
Yescarta (axicabtagene ciloleucel) — anti-CD19 CAR-T for r/r LBCL 2L+ (FDA Apr 2022 ZUMA-7) and r/r FL 3L+ (FDA Mar 2021), Kymriah (tisagenlecleucel) — anti-CD19 CAR-T for B-ALL pediatric/young-adult (FDA Aug 2017), r/r DLBCL 3L+ (FDA May 2018), r/r FL 3L+ (FDA May 2022), Tecartus (brexucabtagene autoleucel) — anti-CD19 CAR-T for r/r MCL (FDA Jul 2020 ZUMA-2) and adult r/r B-ALL (FDA Oct 2021 ZUMA-3), Breyanzi (lisocabtagene maraleucel) — anti-CD19 CAR-T for r/r LBCL 2L+ (FDA Jun 2022 TRANSFORM), r/r CLL/SLL (FDA Mar 2024 TRANSCEND-CLL-004), r/r MCL (FDA May 2024), r/r FL (FDA May 2024), Carvykti (ciltacabtagene autoleucel) — anti-BCMA CAR-T for r/r multiple myeloma 2L+ post-IMiD/anti-CD38 (FDA Apr 2024 CARTITUDE-4 expansion; original FDA Feb 2022 CARTITUDE-1), Abecma (idecabtagene vicleucel) — anti-BCMA CAR-T for r/r multiple myeloma 2L+ after IMiD/PI/anti-CD38 (FDA Apr 2024 KarMMa-3 expansion; original FDA Mar 2021 KarMMa), Bridging chemotherapy (e.g. R-GemOx, R-DHAP, R-ICE, polatuzumab-BR, DPd, KRd) between leukapheresis and CAR-T infusion to control disease, Lymphodepleting chemotherapy — fludarabine 30 mg/m² + cyclophosphamide 300–500 mg/m² days -5 to -3 (per product label)
Ready to fight your denial?
Our free pre-payment review runs before checkout. Refund requests made within 7 calendar days of payment are processed automatically; later requests are reviewed under the Terms. A refund policy is not a promise of a payer outcome.
Start my appeal→